Saturday 17 October 2026 Export AFMDQ’s income statement to Excel — free account

Affimed N.V.

AFMDQ Healthcare Biotechnology

Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.

0.00 0.00 NaN

Follow AFMDQ

Alert me

Market cap: $2.8M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 1/9
Altman Z: −10.41
Beneish M: 15.08
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.13%

Capital & Financial Ratios $m

Market Cap 2.76

Revenue 0.97

Net Income (76.07)

Free Cash Flow (83.32)

Net Debt (18.56)

Current Ratio 1.93

Debt/Equity 0.47

P/E ratio 0.00

Fwd P/E (0.01)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 55.22%

Next Y EPS Growth 22.81%

Next Y revenue growth (87.45%)

Next 5Y EPS Growth 33.62%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/FCF against its own 10 years 26.26%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	234	200	79	27
Receivables	6	3	6	5
Inventory	0	1	1	—
Other	4	3	6	3
	244	207	91	36

	2021	2022	2023	Q'24
Payables	22	20	20	10
ST’ Debt	1	6	6	6
Other	53	10	1	1
	76	37	28	18

Compound Annual Growth %

	10y	5y	3y
Sales	(10.77%)	(20.40%)	(34.86%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	3.15%	5.71%	(8.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	0	—	—
’23	5	2	2	0	9
’22	9	8	15	12	44
’21	14	12	10	12	48
’20	6	3	12	11	32
’19	13	5	2	4	24
’18	1	0	0	27	28

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(18)	(13)	—	—
’23	(36)	(37)	(20)	(27)	(119)
’22	(32)	(27)	(16)	(36)	(111)
’21	(19)	(21)	(29)	(33)	(102)
’20	(18)	(16)	(6)	19	(22)
’19	(15)	(6)	(13)	1	(33)
’18	(9)	(10)	(11)	87	58

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(18)	(12)	—	—
’23	(36)	(37)	(23)	(28)	(123)
’22	(32)	(27)	(16)	(36)	(111)
’22	—	—	—	—	(110)
’21	(20)	(22)	(29)	(36)	(107)
’21	—	—	—	—	(102)
’20	(18)	(17)	(7)	19	(23)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.38)	(1.09)	(1.03)	—	—
’23	(2.30)	(2.20)	(1.70)	(1.45)	(7.67)
’22	(1.60)	(1.40)	(1.10)	(2.20)	(6.30)
’21	0.15	(1.90)	(1.70)	(2.20)	(5.70)
’20	(1.20)	(1.80)	(0.80)	(2.00)	(5.70)
’19	0.30	(1.60)	(1.90)	(2.10)	(5.60)
’18	(1.80)	(1.60)	(2.20)	1.70	(3.80)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	1.65	11.50	1.25	2.18	1.42	4.78	10.30	0.22	Analyst estimates 2024–2026 Powerpack
	High	—	—	7.14	29.50	7.35	4.68	7.46	11.74	57.60	1.35
People
People	Employees	—	—	53	61	69	137	163	197	228	78
	Revenue/emp, $m	—	—	0.13	0.04	0.41	0.17	0.20	0.24	0.19	0.11
Income, $m
Income, $m	Revenue	—	—	7	2	28	24	32	48	44	9
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(36)	(34)	(23)	(36)	(47)	(68)	(91)	(115)
	EBT margin, %	—	—	(511.15)	(1,504.63)	(82.06)	(151.28)	(145.86)	(142.50)	(207.97)	(1,280.19)
	Net income	—	—	(36)	(34)	(23)	(36)	(47)	(68)	(91)	(115)
	Depreciation	—	—	0	0	0	1	1	2	3	2
Per share, $
Per share, $	Revenue	—	—	2.10	0.52	4.63	3.73	3.88	4.00	3.06	0.60
	Earnings	—	—	(10.60)	(7.80)	(3.80)	(5.60)	(5.70)	(5.70)	(6.30)	(7.67)
	Cash flow	—	—	(10.69)	(6.60)	9.65	(5.07)	(2.65)	(8.57)	(7.76)	(7.99)
	Capex	—	—	(0.09)	(0.16)	(0.14)	(0.26)	(0.06)	(0.38)	(0.05)	(0.27)
	Free cash flow	—	—	(10.78)	(6.76)	9.51	(5.32)	(2.72)	(8.95)	(7.81)	(8.26)
	Book value	—	—	12.89	8.16	7.83	6.74	9.85	13.46	11.32	4.19
	Shares, m	—	—	3	4	6	6	8	12	14	15
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	10.00	2.66	0.67	0.73	1.50	1.38	0.40	10.43
	P/B	—	—	1.63	0.17	0.40	0.41	0.59	0.41	0.11	1.49
	EV/Sales	—	—	3.61	(13.60)	(3.71)	(4.02)	(3.67)	(3.08)	(3.78)	3.09
	EV/FCF	—	—	(0.70)	1.04	(1.81)	2.82	5.24	1.37	1.46	(0.22)
Cash, $m
Cash, $m	Operating cash flow	—	—	(36)	(29)	58	(33)	(22)	(102)	(111)	(119)
	Capex	—	—	0	(1)	(1)	(2)	(1)	(5)	(1)	(4)
	Free cash flow	—	—	(36)	(30)	58	(34)	(23)	(107)	(111)	(123)
Balance, $m
Balance, $m	Working capital	—	—	46	39	87	79	96	168	170	63
	Total debt	—	—	5	8	6	3	0	21	19	13
	Net debt	—	—	(45)	(37)	(123)	(114)	(167)	(213)	(182)	(66)
	Shareholders’ equity	—	—	43	36	47	43	82	161	161	63
Returns, %
Returns, %	ROA	—	—	(50.21)	(66.52)	(24.74)	(27.56)	(28.94)	(29.14)	(37.94)	(72.47)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	(60.64)	(86.95)	(55.37)	(79.93)	(75.28)	(55.99)	(56.29)	(102.52)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DCOY Decoy Therapeutics Inc	$2.9M	0.0×	— (loss-making)	−84.61% (below 0%: shrinking)	n/m	−212.47% (below 0%: shrinking)	100.00%	(1,055.98%)	Compare
MBIO Mustang Bio, Inc.	$2.9M	— (loss-making)	—	—	n/m	+27.78% (above 0%: growing)	0.00%	0.00%	Compare
BCAB BioAtla, Inc.	$2.9M	— (loss-making)	— (loss-making)	+4,233.33% (above 0%: growing)	n/m	+97.03% (above 0%: growing)	100.00%	3.49%	Compare
ONCO Onconetix, Inc.	$2.9M	0.0×	— (loss-making)	−83.94% (below 0%: shrinking)	n/m	−36.00% (below 0%: shrinking)	25.15%	(15,969.59%)	Compare
VIVS VivoSim Labs, Inc.	$2.8M	— (loss-making)	— (loss-making)	−51.35% (below 0%: shrinking)	n/m	+17.87% (above 0%: growing)	100.00%	(15,327.78%)	Compare
AFMDQ Affimed N.V.	$2.8M	— (loss-making)	— (loss-making)	−92.02% (below 0%: shrinking)	n/m	+46.95% (above 0%: growing)	100.00%	(9,216.90%)
HCWB HCW Biologics Inc.	$2.8M	— (loss-making)	— (loss-making)	+1,954.55% (above 0%: growing)	n/m	−20.84% (below 0%: shrinking)	(69.25%)	(2,335.03%)	Compare
SLXN Silexion Therapeutics Corp	$2.7M	— (loss-making)	—	—	n/m	−16.63% (below 0%: shrinking)	—	0.00%	Compare
GOVX GeoVax Labs Inc.	$2.6M	— (loss-making)	— (loss-making)	+183.44% (above 0%: growing)	n/m	+15.81% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$2.9M	—	—	+66.05%	—	−0.41%	100.00%	(527.99%)

All 614 Biotechnology stocks →

Affimed N.V. (AFMDQ) key facts

Concern: Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
Affimed N.V. (AFMDQ) is a Biotechnology company in the Healthcare sector.
Return on equity was −102.5% and debt-to-equity 0.47.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −10.41 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.